{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:13:54Z","timestamp":1792084434469,"version":"4.4.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.06.015","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:22:38Z","timestamp":1750677758000},"page":"e1007-e1013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7464-6898","authenticated-orcid":false,"given":"Prerna","family":"Mewawalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dileo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8294-5216","authenticated-orcid":false,"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Strouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-4233","authenticated-orcid":false,"given":"Omar","family":"Alkharabsheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2025.06.015_bib0001","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.06.015_bib0002","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood.2022018157","article-title":"Sequencing anti-BCMA therapies in myeloma","volume":"141","author":"Harousseau","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.06.015_bib0003","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.06.015_bib0004","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.06.015_bib0005","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.06.015_bib0006","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.06.015_bib0007","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.06.015_bib0008","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nature Commun"},{"issue":"9","key":"10.1016\/j.clml.2025.06.015_bib0009","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clml.2025.06.015_bib0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.06.015_bib0011","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.06.015_bib0012","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.06.015_bib0013","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of Teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:09:37Z","timestamp":1763773777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025002186"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}